Agreement - September 17, 2014
AstraZeneca and Eli Lilly enter agreement
The two companies have announced an alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer’s disease. The aim is to progress AZD3293 rapidly into a Phase II/III clinical trial in patients with early Alzheimer’s disease. Lilly will lead clinical development, working with researchers from AstraZeneca’s Innovative Medicines Unit for neuroscience, while AstraZeneca will be responsible […]
Intellectual Property - September 3, 2014
AstraZeneca lost patent controversy
Teva has announced that the UK High Court gives positive judgment in the company’s patent case against AstraZeneca. The case regards the validity of EP 1,085,877 covering the SMART (Single inhaler Maintenance And Reliever Therapy) indication for AstraZeneca’s fixed dose formoterol/budesonide combination product, Symbicort. Teva said that the court agreed with Teva that AstraZeneca’s patent covering […]
Acquisition - August 22, 2014
Pfizer could set eyes on AstraZeneca again
Pfizer could still be interested in buying AstraZeneca, reports Bloomberg refering to individuals with insight into the matter. Pfizer may not get a great shot at buying AstraZeneca this fall but it’s however preparing to give it a try. Meanwhile, Bloomberg reports, the U.S.-based drug giant is looking at Actavis among other targets. The Pfizer management […]
Collaboration - August 21, 2014
AstraZeneca in partnership with Illumina
AstraZeneca has entered into a collaboration with gene sequencing company, Illumina, Inc., to develop its next generation sequencing (NGS) platform for companion diagnostic tests. In the first instance, AstraZeneca intends to apply Illumina’s technology to a novel companion diagnostic test in pivotal studies for one of its investigational oncology compounds. This is expected to be […]
Drug Development Pharma - August 19, 2014
No investigation of Brilinta
The United States Department of Justice has announced that it closes its investigation into PLATO clinical trial for AstraZeneca’s Brilinta. In the PLATO study, Brilinta (ticagrelor) was compared to clopidrogel combined with acetylsalicylic acid. The studied showed that ticagrelor reduced cardiovascular events better than the rival. The Department of Justice started an investigation in October 2013 […]
Clinical Trials - August 14, 2014
AstraZeneca starts phase III program for asthma treatment
AstraZeneca has announced the start of the Phase III programme for tralokinumab, developed by MedImmune. Tralokinumab is a potential treatment for patients with severe, inadequately controlled asthma. The Phase III program will evaluate the safety and effectiveness of tralokinumab in reducing the rate of asthma exacerbations (AER) in adults and adolescents with severe, inadequately controlled asthma despite receiving […]
